Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

The Defense Health Agency Aurora, on behalf of the Tricare Management Activity, has issued solicitation HT9402-26-Q-9203 to support the Department of War (DoW) Uniform Formulary and the Pharmacy Uniform Formulary Additional Discount Program. This requirement facilitates an integrated pharmacy benefits program for the Military Health System as mandated by 10 U.S.C. § 1074g and 32 CFR Section 199.21. The agency intends to award Uniform Formulary Blanket Purchase Agreements and Uniform Formulary Additional Discount Program Agreements based on clinical and cost-effectiveness recommendations from the DoW Pharmacy and Therapeutics Committee. Performance is centered in San Antonio, Texas, under NAICS 325412 Pharmaceutical Preparation Manufacturing and PSC 6505 Drugs and Biologicals.

The scope involves the review and selection of various pharmaceutical agents for classification as generic, formulary, Basic Core Formulary, Extended Core Formulary, or non-formulary. Specific drug classes scheduled for review in May 2026 include ADHD stimulants, skeletal muscle relaxants, antilipidemics, and agents for metabolic dysfunction, weight loss, and growth stimulation. The procurement includes 14 attachments such as price lists, frequently asked questions, and drug-specific appendices for newly approved products like Arynta, Lerochol, and Yuviwel.

Responses to this solicitation are due by April 27, 2026. A pre-quotation teleconference is scheduled for April 15, 2026, to discuss the requirements and the submission process for clinical questions. Submissions must be directed to the point of contact, Stephanie Erpelding, in accordance with the instructions provided in the request for quotation. Primary identifiers for this action include the published date of April 10, 2026, and the associated solicitation number HT9402-26-Q-9203.